Chromane compounds
    1.
    发明授权
    Chromane compounds 有权
    色烷化合物

    公开(公告)号:US09242973B2

    公开(公告)日:2016-01-26

    申请号:US14603110

    申请日:2015-01-22

    申请人: CoMentis, Inc.

    摘要: The present invention provides a hydrate of N-[(4S)-2-amino-2′,2′-dimethyldispiro[1,3-oxazole-4,4′-chromene-3′,3″-oxetan]-6′-yl]-5-chloropyridine-2-carboxamide which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β-amyloid precursor protein, and/or β-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.

    摘要翻译: 本发明提供N - [(4S)-2-氨基-2',2'-二甲基二螺[1,3-唑-4,4'-色烯-3',3“氧杂an an] -6' - 基] -5-氯吡啶-2-甲酰胺,其可用作药物组合物的活性成分,特别是用于预防或治疗与分泌酶活性相关和/或介导的疾病或病症的药物组合物,水解 包括淀粉样前体蛋白质和/或淀粉样蛋白前体蛋白质的分泌酶位点和/或淀粉样蛋白质积累,包括用于预防或治疗疾病的药物组合物,包括但不限于青光眼,MCI(轻度认知障碍) 或阿尔茨海默病,特别是阿尔茨海默氏病。

    Chromane compounds
    2.
    发明授权
    Chromane compounds 有权
    色烷化合物

    公开(公告)号:US08975415B2

    公开(公告)日:2015-03-10

    申请号:US14192667

    申请日:2014-02-27

    申请人: CoMentis, Inc.

    IPC分类号: C07D263/52 C07D493/00

    摘要: The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β-amyloid precursor protein, and/or β-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.

    摘要翻译: 本发明提供了一种化合物,其可用作药物组合物的活性成分,特别是用于预防或治疗与分泌酶活性相关和/或介导的疾病或病症的药物组合物, 包括淀粉样蛋白前体蛋白的分泌酶位点和/或β-淀粉样蛋白积聚,包括用于预防或治疗疾病的药物组合物,包括但不限于青光眼,MCI(轻度认知障碍)或阿尔茨海默病,特别是 , 阿尔茨海默氏病。